Michael M Givertz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7666122/publications.pdf

Version: 2024-02-01

167 papers 17,414 citations

52 h-index 129 g-index

167 all docs

167
docs citations

167 times ranked

17136 citing authors

#	Article	IF	CITATIONS
1	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for theÂManagement of Heart Failure. Journal of the American College of Cardiology, 2017, 70, 776-803.	1.2	2,256
2	Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New England Journal of Medicine, 2011, 364, 797-805.	13.9	1,363
3	HFSA 2010 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure, 2010, 16, e1-e2.	0.7	1,086
4	Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2013, 309, 1268.	3.8	976
5	Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. New England Journal of Medicine, 2012, 367, 2296-2304.	13.9	790
6	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1476-1488.	1,2	549
7	2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for theÂManagement of Heart Failure. Journal of Cardiac Failure, 2017, 23, 628-651.	0.7	531
8	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America, Circulation, 2016, 134, e282-93.	1.6	494
9	2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care. Journal of the American College of Cardiology, 2015, 65, e7-e26.	1.2	491
10	Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2016, 316, 500.	3.8	457
11	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. JAMA - Journal of the American Medical Association, 2013, 310, 2533.	3.8	410
12	Secondary Pulmonary Hypertension in Chronic Heart Failure. Circulation, 2000, 102, 1718-1723.	1.6	366
13	Impact of Oxypurinol in Patients With Symptomatic Heart Failure. Journal of the American College of Cardiology, 2008, 51, 2301-2309.	1.2	350
14	Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency. JAMA - Journal of the American Medical Association, 2017, 317, 1958.	3.8	329
15	Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure, 2015, 21, 519-534.	0.7	283
16	Genetic Evaluation of Cardiomyopathy—A Heart Failure Society of America Practice Guideline. Journal of Cardiac Failure, 2018, 24, 281-302.	0.7	280
17	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. European Heart Journal, 2014, 35, 1284-1293.	1.0	276
18	Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. New England Journal of Medicine, 2019, 380, 1606-1617.	13.9	266

#	Article	IF	Citations
19	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. Circulation, 2015, 131, 1763-1771.	1.6	239
20	World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adultâ€"a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2012, 31, 913-933.	0.3	210
21	Efficacy and Safety of Spironolactone in Acute Heart Failure. JAMA Cardiology, 2017, 2, 950.	3.0	199
22	Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2017, 70, 1875-1886.	1.2	198
23	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2018, 320, 1764.	3.8	187
24	Mechanical Circulatory Support for Advanced Heart Failure. Circulation, 2012, 125, 1304-1315.	1.6	182
25	The Effects of KW-3902, an Adenosine A1-Receptor Antagonist, on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure and Renal Impairment or Diuretic Resistance. Journal of the American College of Cardiology, 2007, 50, 1551-1560.	1.2	162
26	Signature of circulating <scp>microRNAs</scp> in patients with acute heart failure. European Journal of Heart Failure, 2016, 18, 414-423.	2.9	162
27	Clinical Course of Patients With Worsening Heart Failure With ReducedÂEjection Fraction. Journal of the American College of Cardiology, 2019, 73, 935-944.	1.2	160
28	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. International Journal of Cardiology, 2018, 258, 185-191.	0.8	157
29	Heart Failure With Recovered Ejection Fraction: A Distinct Clinical Entity. Journal of Cardiac Failure, 2011, 17, 527-532.	0.7	134
30	Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study. Circulation, 2019, 139, 155-168.	1.6	113
31	2015 SCAI/ACC/HFSA/STS Clinical Expert Consensus Statement on the use of Percutaneous Mechanical Circulatory Support Devices in Cardiovascular Care (Endorsed by the American Heart Association, the) Tj ETQq1 1	0.784314 0.7	rgBT /Over
32	Peripartum cardiomyopathy. BMJ: British Medical Journal, 2019, 364, k5287.	2.4	99
33	Marijuana Use in Patients With CardiovascularÂDisease. Journal of the American College of Cardiology, 2020, 75, 320-332.	1.2	91
34	Considerations for HeartÂFailure Care During the COVID-19 Pandemic. JACC: Heart Failure, 2020, 8, 681-691.	1.9	89
35	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	80
36	Comparing CMR Mapping Methods andÂMyocardial Patterns Toward HeartÂFailure Outcomes in NonischemicÂDilated Cardiomyopathy. JACC: Cardiovascular Imaging, 2019, 12, 1659-1669.	2.3	80

#	Article	IF	CITATIONS
37	2015 SCAI/ACC/HFSA/STS Clinical ExpertÂConsensus Statement on the Use ofÂPercutaneous Mechanical Circulatory SupportÂDevices in Cardiovascular Care. Journal of the American College of Cardiology, 2015, 65, 2140-2141.	1.2	78
38	Biomarker Profiles of AcuteÂHeartÂFailureÂPatients With aÂMid-Range EjectionÂFraction. JACC: Heart Failure, 2017, 5, 507-517.	1.9	78
39	Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2022, 7, 17.	3.0	77
40	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. Heart, 2017, 103, 407-413.	1.2	74
41	Early Management of Patients With Acute Heart Failure: State of the Art and Future Directions. A Consensus Document From the Society for Academic Emergency Medicine/Heart Failure Society of America Acute Heart Failure Working Group. Journal of Cardiac Failure, 2015, 21, 27-43.	0.7	73
42	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the <scp>PROTECT</scp> study. European Journal of Heart Failure, 2016, 18, 830-839.	2.9	70
43	Remote Monitoring of Patients With Heart Failure: A White Paper From the Heart Failure Society of America Scientific Statements Committee. Journal of Cardiac Failure, 2018, 24, 682-694.	0.7	70
44	Optimizing clinical use of biomarkers in highâ€risk acute heart failure patients. European Journal of Heart Failure, 2016, 18, 269-280.	2.9	69
45	Epidemiology and Natural History of Recovery of Left Ventricular Function in Recent Onset Dilated Cardiomyopathies. Current Heart Failure Reports, 2013, 10, 321-330.	1.3	68
46	Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy. JACC: Heart Failure, 2016, 4, 380-388.	1.9	68
47	Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction. Circulation, 2007, 115, 1218-1224.	1.6	66
48	Ventricular Assist Devices. Circulation, 2011, 124, e305-11.	1.6	63
49	Acute heart failure. Trends in Cardiovascular Medicine, 2020, 30, 104-112.	2.3	62
50	Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. Circulation: Heart Failure, 2014, 7, 59-67.	1.6	60
51	Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion. Circulation: Heart Failure, 2018, 11, e004644.	1.6	58
52	Trends in US Heart Transplant Waitlist Activity and Volume During the Coronavirus Disease 2019 (COVID-19) Pandemic. JAMA Cardiology, 2020, 5, 1048.	3.0	58
53	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Tj ETQq1	1 0078431	.4 rg/BT /Оver
54	Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis. Circulation: Cardiovascular Imaging, 2019, 12, e008975.	1.3	54

#	Article	IF	Citations
55	Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. Journal of Cardiac Failure, 2013, 19, 371-389.	0.7	53
56	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. International Journal of Cardiology, 2016, 224, 231-239.	0.8	53
57	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. European Journal of Heart Failure, 2017, 19, 1310-1320.	2.9	53
58	Patient journey after admission for acute heart failure: length of stay, 30â€day readmission and 90â€day mortality. European Journal of Heart Failure, 2016, 18, 1041-1050.	2.9	49
59	Variable Contribution of Heart Failure toÂQuality of Life in Ambulatory HeartÂFailure With Reduced, Better, orÂPreserved Ejection Fraction. JACC: Heart Failure, 2016, 4, 184-193.	1.9	48
60	Challenges in Heart Transplantation in the Era of COVID-19. Circulation, 2020, 141, 2048-2051.	1.6	47
61	Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	46
62	Antioxidants and Myocardial Contractility. Circulation, 2001, 103, 782-783.	1.6	44
63	Worsening Heart Failure Following Admission for Acute Heart Failure. JACC: Heart Failure, 2015, 3, 395-403.	1.9	44
64	Trends and Outcomes of Left Ventricular Assist Device Therapy. Journal of the American College of Cardiology, 2022, 79, 1092-1107.	1.2	41
65	Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. Journal of Cardiac Failure, 2015, 21, 674-693.	0.7	39
66	Early aspirin use and the development of cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2017, 36, 1344-1349.	0.3	39
67	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) Tj ETQq $1\ 1\ 0$.784314 r 0.7	gBT/Overlo
68	Sacubitril/Valsartan in Advanced HeartÂFailure With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 789-799.	1.9	39
69	Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	38
70	Myocardial Damage Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Uncommon in Peripartum Cardiomyopathy. Journal of the American Heart Association, 2017, 6, .	1.6	38
71	Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation. Journal of the American College of Cardiology, 2019, 74, 36-51.	1.2	37
72	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	35

#	Article	IF	CITATIONS
73	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. International Journal of Cardiology, 2016, 203, 564-569.	0.8	35
74	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. International Journal of Cardiology, 2016, 204, 164-171.	0.8	34
75	Plasma biomarkers to predict or rule out early postâ€discharge events after hospitalization for acute heart failure. European Journal of Heart Failure, 2017, 19, 728-738.	2.9	34
76	Worsening renal function in acute heart failure in the context of diuretic response. European Journal of Heart Failure, 2022, 24, 365-374.	2.9	34
77	Evolving Areas in Heart Transplantation. JACC: Heart Failure, 2017, 5, 869-878.	1.9	33
78	Clinical value of preâ€discharge bioâ€adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. European Journal of Heart Failure, 2020, 22, 683-691.	2.9	33
79	Plasma kidney injury moleculeâ€1 in heart failure: renal mechanisms and clinical outcome. European Journal of Heart Failure, 2016, 18, 641-649.	2.9	32
80	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. Clinical Research in Cardiology, 2016, 105, 145-153.	1.5	32
81	SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease. Catheterization and Cardiovascular Interventions, 2017, 89, E233-E247.	0.7	32
82	Advanced HeartÂFailure Therapies forÂAdults With CongenitalÂHeartÂDisease. Journal of the American College of Cardiology, 2019, 74, 2295-2312.	1.2	32
83	Outcomes in the 2018 UNOS donor heart allocation system: A perspective on disparate analyses. Journal of Heart and Lung Transplantation, 2020, 39, 1191-1194.	0.3	31
84	Peripartum Cardiomyopathy. Circulation, 2013, 127, e622-6.	1.6	30
85	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2017, 23, 231-239.	0.7	30
86	Prevalence of polyreactive innate clones among graft-Âɨnfiltrating B cells in human cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2018, 37, 385-393.	0.3	30
87	Arrhythmias in Peripartum Cardiomyopathy. Cardiac Electrophysiology Clinics, 2015, 7, 309-317.	0.7	29
88	Electrocardiographic findings in peripartum cardiomyopathy. Clinical Cardiology, 2019, 42, 524-529.	0.7	29
89	Assessment and Management of Heart Failure After Left Ventricular Assist Device Implantation. Circulation, 2014, 129, 1161-1166.	1.6	27
90	Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. Journal of Heart and Lung Transplantation, 2014, 33, 372-381.	0.3	26

#	Article	IF	CITATIONS
91	Thrombus around the redesigned HeartWare HVAD inflow cannula: A pathologic case series. Journal of Heart and Lung Transplantation, 2016, 35, 926-930.	0.3	26
92	Hyperkalemia and Treatment With RAASÂInhibitors During Acute HeartÂFailure Hospitalizations and TheirÂAssociation With Mortality. JACC: Heart Failure, 2019, 7, 970-979.	1.9	26
93	circulatory support devices in cardiovascular care (Endorsed by the American heart assocation, the) Tj ETQq1 1 (0.784314 i 0.7	gBT /Overloc 25
94	E175-96. Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. European Journal of Heart Failure, 2015, 17, 697-706.	2.9	24
95	Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiology, 2015, 11, 585-595.	0.5	23
96	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. Journal of Cardiac Failure, 2022, 28, 1063-1077.	0.7	23
97	Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients. Circulation: Heart Failure, 2013, 6, 862-868.	1.6	21
98	Cerebrovascular Accidents During Mechanical Circulatory Support. Stroke, 2018, 49, 1197-1203.	1.0	21
99	HFSA/SAEM/ISHLT clinical expert consensus document on the emergency management of patients with ventricular assist devices. Journal of Heart and Lung Transplantation, 2019, 38, 677-698.	0.3	18
100	Cardiac Sarcoidosis: When and How to Treat Inflammation. Cardiac Failure Review, 2021, 7, e17.	1.2	18
101	Early vitamin C and E supplementation and cardiac allograft vasculopathy: 10-Year follow-up from a randomized, controlled study. Journal of Heart and Lung Transplantation, 2011, 30, 1200-1201.	0.3	17
102	Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure. International Journal of Molecular Sciences, 2017, 18, 1470.	1.8	17
103	Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices. Journal of Thrombosis and Thrombolysis, 2018, 46, 180-185.	1.0	16
104	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2019, 25, 866-874.	0.7	16
105	HFSA/SAEM/ISHLT Clinical Expert Consensus Document on the Emergency Management of Patients with Ventricular Assist Devices. Journal of Cardiac Failure, 2019, 25, 494-515.	0.7	16
106	Evolving Characteristics of Heart Transplantation Donors and Recipients. Journal of the American College of Cardiology, 2022, 79, 1108-1123.	1.2	16
107	Lower urine sodium predicts longer length of stay in acute heart failure patients: Insights from the ROSE AHF trial. Clinical Cardiology, 2020, 43, 43-49.	0.7	14
108	Sex Differences in Exercise Capacity and Quality of Life in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of the RELAX and NEAT-HFPEF Trials. Journal of Cardiac Failure, 2020, 26, 276-280.	0.7	14

#	Article	IF	Citations
109	Pump thrombosis redux. Journal of Heart and Lung Transplantation, 2015, 34, 1511-1514.	0.3	12
110	Maternal Obesity Affects Cardiac Remodeling and Recovery in Women with Peripartum Cardiomyopathy. American Journal of Perinatology, 2019, 36, 476-483.	0.6	12
111	B cell clonal expansion within immune infiltrates in human cardiac allograft vasculopathy. American Journal of Transplantation, 2020, 20, 1431-1438.	2.6	12
112	Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENAâ€HF trial. European Journal of Heart Failure, 2020, 22, 1451-1461.	2.9	12
113	Resource utilization and costs among patients with heart failure with reduced ejection fraction following a worsening heart failure event. ESC Heart Failure, 2021, 8, 1915-1923.	1.4	12
114	Participation in a Heart Failure Clinical Trial. Circulation: Heart Failure, 2021, 14, e008242.	1.6	12
115	Increased Opportunities for Transplantation for Women in the New Heart Allocation System. Journal of Cardiac Failure, 2022, 28, 1149-1157.	0.7	12
116	Acute heart failure in the young: Clinical characteristics and biomarker profiles. International Journal of Cardiology, 2016, 221, 1067-1072.	0.8	11
117	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	11
118	Executive Summary of the SCAI/HFSA Clinical Expert Consensus Document on the Use of Invasive Hemodynamics for the Diagnosis and Management of Cardiovascular Disease. Journal of Cardiac Failure, 2017, 23, 487-491.	0.7	11
119	Early immune biomarkers and intermediate-term outcomes after heart transplantation: Results of Clinical Trials in Organ Transplantation-18. American Journal of Transplantation, 2019, 19, 1518-1528. 2015 <scp>SCAI</scp> / <scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<scp>/<s< td=""><td>2.6</td><td>11</td></s<></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp></scp>	2.6	11
120	statement on the use of percutaneous mechanical circulatory support devices in Cardiovascular Care (Endorsed by the American heart association, the Cardiological society of India, and Sociedad Latino) Tj ETQq0 0	OrgBT/O	verlock 10 Tf
121	Cardiovascular Interventions, 2015, 85, 1112-1114 Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. Academic Emergency Medicine, 2016, 23, 922-931.	0.8	10
122	Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961983736.	0.7	10
123	T cell repertoire analysis suggests a prominent bystander response in human cardiac allograft vasculopathy. American Journal of Transplantation, 2021, 21, 1465-1476.	2.6	10
124	Discharge Outcomes in Patients With Paracorporeal Biventricular Assist Devices. Annals of Thoracic Surgery, 2014, 97, 894-900.	0.7	8
125	Assessing the liver to predict outcomes in heart transplantation. Journal of Heart and Lung Transplantation, 2015, 34, 869-872.	0.3	8
126	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. Cardiovascular Drugs and Therapy, 2017, 31, 281-293.	1.3	8

#	Article	IF	CITATIONS
127	Expanding the Donor Pool With Use of Hepatitis C Infected Hearts. Circulation: Heart Failure, 2018, 11, e005656.	1.6	8
128	Variability in Blood Pressure Assessment in Patients Supported with the HeartMate 3TM. ASAIO Journal, 2022, 68, 374-383.	0.9	8
129	Marijuana use and candidacy for heart transplantation. Journal of Heart and Lung Transplantation, 2019, 38, 589-592.	0.3	7
130	Annexin A1 is a Potential Novel Biomarker of Congestion in Acute Heart Failure. Journal of Cardiac Failure, 2020, 26, 727-732.	0.7	7
131	Remote Hemodynamic Monitoring Equally Reduces Heart Failure Hospitalizations in Women and Men in Clinical Practice: A Sex-Specific Analysis of the CardioMEMS Post-Approval Study. Circulation: Heart Failure, 2021, 14, e007892.	1.6	7
132	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 808-811.	0.7	7
133	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure â€" Post-hoc analysis of the PROTECT trial. International Journal of Cardiology, 2016, 223, 967-975.	0.8	6
134	Virtual Health During a Pandemic. Circulation: Heart Failure, 2020, 13, e007317.	1.6	6
135	Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in heart transplantation. Clinical Transplantation, 2021, 35, e14424.	0.8	6
136	Left ventricular dimension decrement index early after axial flow assist device implantation: A novel risk marker for late pump thrombosis. Journal of Heart and Lung Transplantation, 2015, 34, 1561-1569.	0.3	5
137	Sizing it up in heart transplantation: Time to change the guidelines?. Journal of Heart and Lung Transplantation, 2019, 38, 133-135.	0.3	5
138	Response to Sexton: Inhibiting the Renin–Angiotensin–Aldosterone System in Patients With Heart Failure and Renal Dysfunction. Circulation: Heart Failure, 2014, 7, 537-540.	1.6	4
139	Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit. Current Heart Failure Reports, 2016, 13, 111-118.	1.3	4
140	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. Journal of Cardiac Failure, 2016, 22, 618-627.	0.7	4
141	Executive summary of the SCAI/HFSA clinical expert consensus document on the use of invasive hemodynamics for the diagnosis and management of cardiovascular disease. Catheterization and Cardiovascular Interventions, 2017, 89, 1294-1299.	0.7	4
142	Treating Gout in Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2018, 71, 1005-1008.	1.2	4
143	Patients report more severe daily limitations than recognized by their physicians. Clinical Cardiology, 2019, 42, 1181-1188.	0.7	4
144	Proinflammatory TH17 cytokine activation, disease severity and outcomes in peripartum cardiomyopathy. International Journal of Cardiology, 2021, 339, 93-98.	0.8	4

#	Article	IF	Citations
145	The Challenge of Drug Development in Acute Heart Failure. JACC: Heart Failure, 2013, 1, 442-444.	1.9	3
146	Impact of pre-diabetes on heart transplant outcomes in patients with advanced heart failure. Journal of Heart and Lung Transplantation, 2014, 33, 215-217.	0.3	3
147	Turning Failure into Success: Trials of the Heart Failure Clinical Research Network. Current Cardiology Reports, 2016, 18, 121.	1.3	3
148	Prothrombin Complex Concentrate for Non-Bleeding Urgent Warfarin Reversal in Ventricular Assist Device Patients Undergoing Heart Transplantation. Current Emergency and Hospital Medicine Reports, 2016, 4, 93-97.	0.6	3
149	Disparities in Wait-List Outcomes for Adults With Congenital Heart Disease Listed for Heart Transplantation Before and Since Revision of Status I Listing. American Journal of Cardiology, 2018, 122, 1761-1764.	0.7	3
150	Cancer and the Heart: Training Subspecialists, Optimizing Care, and Moving the Field Forward. Journal of Cardiac Failure, 2016, 22, 472-474.	0.7	2
151	Resource utilization and hospital readmission associated with gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices. Journal of Thrombosis and Thrombolysis, 2019, 47, 375-383.	1.0	2
152	Postoperative bridging anticoagulation and left ventricular assist system thrombosis. Journal of Thrombosis and Thrombolysis, 2019, 47, 57-66.	1.0	2
153	Predicting Outcomes in Heart Transplantation. Circulation: Cardiovascular Imaging, 2014, 7, 857-859.	1.3	1
154	Testing Medical Fairness. Circulation: Heart Failure, 2019, 12, e006517.	1.6	1
155	Metabolic Cardiomyopathy, 2nd ed Circulation, 2004, 110, .	1.6	O
156	Response to Letter Regarding Article, $\hat{a} \in \infty$ Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships $\hat{a} \in \mathbb{R}$ Circulation, 2007, 116, .	1.6	0
157	Therapeutic Strategies in Heart Failure. Circulation, 2008, 118, .	1.6	O
158	What is Old is Now New: Insights into Cardiorenal Physiology. Journal of Cardiac Failure, 2014, 20, 920-922.	0.7	0
159	Advanced Therapies for Advanced Heart Failure: Time to Raise Awareness. Heart Failure Clinics, 2016, 12, ix-x.	1.0	0
160	A heart within a heart. Catheterization and Cardiovascular Interventions, 2017, 89, 1239-1241.	0.7	0
161	87. Heart and Lung Transplants From HCV-Viremic Donors to Uninfected Patients: Longer-Term Follow-Up. Open Forum Infectious Diseases, 2019, 6, S5-S5.	0.4	0
162	Mobile Geolocation Technology to Improve Multidisciplinary Care of Patients With Ventricular Assist Devices: A Feasibility Study. Critical Pathways in Cardiology, 2019, 18, 47-50.	0.2	0

#	Article	IF	CITATIONS
163	An Emergency Medicine–focused Summary of the HFSA/SAEM/ISHLT Clinical Consensus Document on the Emergency Management of Patients With Ventricular Assist Devices. Academic Emergency Medicine, 2020, 27, 618-629.	0.8	0
164	Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure. Journal of Physiology and Biochemistry, 2021, 77, 295-304.	1.3	0
165	Letter by DeFilippis et al Regarding Article, "Sex Disparities in the Management and Outcomes of Cardiogenic Shock Complicating Acute Myocardial Infarction in the Young― Circulation: Heart Failure, 2021, 14, e008033.	1.6	0
166	Abstract 11074 : Worsening Renal Function in Acute Heart Failure in the Context of Diuretic Response. Circulation, 2021, 144, .	1.6	0
167	The role of sensitization in post-transplant outcomes in adults with congenital heart disease sensitization in adults with congenital heart disease. International Journal of Cardiology Congenital Heart Disease, 2022, , 100384.	0.2	0